Biotech europe. In our online store you can purchase BioTechUSA supplements directly from the manufacturer, such as protein powders (including Iso Whey Zero, Europe's favorite protein product), pre-workout formulas, vitamins, mass gainers, amino acids, functional foods, and more. A curated look at leading European biotech companies—what they’re building, where the market is headed, and the trends shaping the next wave of innovation. Its primary purpose is to create an environment that encourage companies to conduct research, development, and manufacturing within the EU. 1 The MDR, introduced The share price of London-based Compass Pathways soared over 30% on Tuesday after the company reported that its synthetic psilocybin formulation COMP360 had met the primary endpoint in the second of two pivotal phase III trials in treatment-resistant depression (TRD), confirming consistent results across 839 patients and clearing the path toward what would be the first regulatory filing of a Anticipated in a non-binding biotech initiative3 launched in March 2024, the act aims to simplify regulatory processes for the life sciences sector and is a crucial part of the broader drive to enhance European competitiveness. A compound annual growth rate of 13. World Class Lab As a world class lab, BIOTECH (BIOTECH EUROPE) ensures the quality of its products by utilizing state-of-the-art facilities, advanced technology and cutting edge systems. 2% is expected of Europe biotechnology market from 2024 to 2030. On behalf of the European Biotechnology Thematic Network Association (EBTNA), we are delighted to invite you to the European Biotechnology Congress 2026 (EuroBiotech 2026), a premier international event bringing together the multifaceted impacts and future potential of biotechnology. Biotech Healthcare announced that it has achieved certification under the European Union’s Medical Device Regulation (MDR) across a range of ophthalmic and medical devices, supporting its continued presence in the European market. Measures include a new EU investment facility to make it easier for biotech companies to access funding targeted support for high-impact projects to boost bio-manufacturing We take a look at Oxford’s biotech and life sciences hub to discover what makes this historical city a hotspot for scientific innovation. The European Commission is proposing sweeping new legislation aimed at reinvigorating Europe’s biotech sector. Dec 19, 2025 · A Vision for a World-Leading European Biotech Industry? The EU Biotech Act represents a comprehensive legislative proposal with the potential to significantly influence Europe’s health biotechnology sector. The strengthened collaboration will extend beyond BIO-Europe Spring, continuing and evolving throughout 2026 in the lead-up to BIO-Europe, further embedding investor insight into the company The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January 2026. Find the most up-to-date statistics about biotechnology in Europe Germany and France have the highest number of biotech patent applicants in the EU, accounting for over half of all EU biotech patents. The certification supports continued European market access as the Medical Device Regulation imposes stricter requirements on manufacturers. 7% of all the biotech patents analysed. Now, after months of anticipation, the publication of the Proposal for the European Biotech Act (Biotech Act I) provides the clearest signal yet of the EU’s determination to strengthen biopharmaceutical innovation, clinical research, and manufacturing in Europe. DIRECTIVE 98/44/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 July 1998 on the legal protection of biotechnological inventions THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty establishing the European Community, and in particular Article 100a thereof, Having regard to the proposal from the Commission (1), Having regard to the opinion of the European biotech companies continued to raise unprecedented amounts of capital last year. Join 5,800+ life science professionals at BIO-Europe 2025 in Vienna, November 3-5. Von der Leyen's political manifesto states that Europe could capitalise The EU Biotech Act is Europe’s opportunity to create a cornerstone for this strategically critical technology. Connect, fund, scale, and innovate with early to growth-stage companies, investors, and strategic partners. Directorate-General for Health & Food Safety (DG SANTE) is responsible for protecting the health of EU citizens, as well as animal health and welfare, plant health and food safety, through a One Health approach. LOS ANGELES, CA - February 18, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the The European biotech industry is bustling with activity this year. Capital is available globally; Europe is struggling to capture it. It is used in a variety of industrial sectors such as textiles, chemicals, plastic, paper, food, feed, pharmaceuticals, and fuel processing. Learn more about the biotech and biopharma industry in Europe, including market trends, investments, fundraisings, M&A, and collaborations. This report offers a new perspective on the Europe Biotechnology Market covering an extensive range of aspects including market overview, expenditure analysis, import trends, segmentation, key The European Life Sciences Coalition marks a significant step toward a more coordinated and well-funded European biotech ecosystem. By combining the expertise of leading investors, research institutions, and policy influencers, the coalition aims to boost investment, accelerate innovation, and strengthen Europe’s position in the global life The European Commission has approved Amgen’s Uplizna in generalized myasthenia gravis, moving the big biotech into a market served by argenx, Johnson & Johnson and UCB. The EU has an innovative and competitive biotech industry, whilst AI is set to accelerate many biotech innovations and developments. Find the top upcoming international biotech conferences, events, seminars, webinars, and workshops for 2026! Europe produces world-class life sciences research, yet still struggles to finance and scale it. William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage biotechs in the bunch. European startups that develop scalable, cost-efficient biotechnological solutions for food production position themselves for export and international collaboration. The strengthened collaboration will extend beyond BIO-Europe Spring, continuing and evolving throughout 2026 in the lead-up to BIO-Europe, further embedding investor insight into the company Proposal for a Regulation to establish measures to strengthen the Union's biotechnology and biomanufacturing sectors (European Biotech Act) The life sciences world is evolving faster than ever. Discover 10 European biotech companies likely to make a big splash. 3 Days BioTechX: Europe's largest event covering data, AI and genomics BioTechX connects every vertical across the entire biotech and pharmaceutical ecosystem – drug discovery, clinical trials, R&D, data science, tech pioneers, investors, and pharma leaders - with a focus on innovation , data integration , and accelerating therapeutic WHY A BIOTECH ACT ? EU Competitiveness - Enhancing the EU’s ability to compete globally and as a leader in biotech. European Biotechnology Biotechnology plays an important role across Europe and has been acknowledged as a key enabling technology for the implementation of the bioeconomy. 4 million by 2030. Europe has a complex biotech landscape: hundreds of companies, multiple paths to innovation and financing, and marked differences among countries. That sets itself apart from its competitors and make its quality control and assurance implemented at every level of its whole supply chain. Europe's largest spring biotech conference. Job Creation - Creating thousands of quality jobs and boosting European economies. At the same time, the potential of biotechnology and biomanufacturing has also been recognised by other countries 5 . Europe produces world-class life Building a world-leading health biotech industry The Commission has proposed a biotech act to support innovation and increase Europe's biotechnology potential. Connect with global biopharma leaders and drive strategic partnerships forward. BIO-Europe Spring 2026 brings together 3,700+ executives for strategic partnerships, March 23-25, Lisbon, Portugal. Dec 17, 2025 · Yesterday’s package of health sector-focused measures from the European Commission contains a number of flagship deliverables under the July 2025 EU Life Sciences Strategy, including the first of two planned EU Biotech Acts and proposals to simplify the EU regulations on medical devices and in vitro diagnostics. Biotech breakthroughs, medtech innovation, and pharmatech transformation are reshaping the industry, and investors, founders, and executives As the largest global non-profit biotechnology trade association representing startups to Fortune 500 companies, BIO is proud to host a portfolio of partnering conferences that not only unite and empower biotech innovators and their ecosystem to improve lives, but also offer a broad and unbiased venue to seek investment and BD&L opportunities. Feb 13, 2026 · Biotechnology in view To create visibility and recognition for the contribution of biotechnology and biomanufacturing within Europe’s societal, environmental and economic ambitions. Below is the list of 100 best universities for Biotechnology in Europe ranked based on their research performance: a graph of 25M citations received by 618K academic papers made by these universities was used to calculate ratings and create the top. Dec 17, 2025 · The new EU Biotech Plan wants to keep research, clinical development, and manufacturing within the European Union. Therefore, biotechnology is part of not only the EU’s but also several national and regional bioeconomy related strategy documents. European biotech companies continued to raise unprecedented amounts of capital last year. Biotechnology is one of the EU's fastest-growing innovative industries, characterised by high labour productivity. Biotechnology helps the EU to modernise its industry and agriculture, forestry, energy, food and feed sectors. Companies have an opportunity to play a stronger role in biotech in Europe by focusing on three factors. Check EU rules for developing your biotech and biomanufacturing business, find research infrastructures, and scale up your business with access to networks, funding, and market insights. The single biotechnology most patented falls under the C12Q 1/68 category "Measuring or testing processes involving nucleic acids", which alone represents 5. It aims to mobilise public and private capital more effectively to finance, scale, and retain its life sciences innovation at home. Venture capital in European biotech accounts for just 7 per cent of global funding, while 66 of the 67 EU biotech companies that went public over the past six years chose to list outside Europe. European Biotechnology is the first and foremost information platform reporting on the life sciences in Europe. In 2026, the Commission will address the wider biotech ecosystem beyond health, to ensure a competitive internal market for all areas of biotechnology. While the combination achieved a notable improvement in progression-free survival (PFS), the study narrowly missed its predefined statistical threshold for significance. Discover the key biotech trends moving the industry forward in Europe at a time when there lies uncertainty in global policies. | William Blair has hand-picked its top five stock IO Biotech has published top-line results from its pivotal Phase 3 trial evaluating the therapeutic cancer vaccine IO102-IO103 (Cylembio) in combination with pembrolizumab in patients with advanced melanoma. Dec 16, 2025 · The Biotech Act aims to help Europe in its struggle to translate world-class life sciences research into commercial success by tackling the structural barriers that have driven start-ups abroad, including the funding gap for biotech companies and the EU’s declining share in clinical trials. We work to build a strong European Health Union, to improve public health and boost health preparedness and resilience in our Union. It is vital that biotech is recognised at a high policy level, and a strong Biotech Act sends a global signal that our innovation and capacity will support healthy citizens, competitive sectors and a sustainable future. Biotechnology in action To deliver intellectual property, skills, capacity and investment from Europe’s innovation excellence. This cluster World-class science and innovation need to be matched with stronger scale-up capabilities and a broader funding base if Europe is to emerge as a leader in biotech. The EU Biotech Act must maximise Europe’s global impact and position this strategic technology, with an ambitious, cross-sectoral approach. To see through the complexity, we grouped approximately 1,000 European biotech companies into clusters by country, modality, and therapeutic area so as to map biotech hot spots and trace how trends in the region are shifting over time. A more-competitive biotechnology sector will offer patients timely and broader access to treatments and products, improved healthcare and a better quality of life. We plotted out 1,382 European biotech companies by country, modality and therapeutic area and nine clusters emerged. From the latest seed rounds to Series A, B, C, D, IPOs, PIPE investments, and beyond, stay updated on the most recent biotech fundings! The European Life Sciences Coalition (ELSC), in association with Invest Europe, a new initiative to strengthen Europe’s life sciences venture capital (VC) ecosystem. Join LSX Europe, the leading event for life science and healthcare leaders, in Lisbon, Portugal, March 25-26, 2026. Can they survive what are likely to be leaner times ahead? The biotechnology market in Europe is expected to reach a projected revenue of US$ 1,144,370. As Europe’s top biotech website for over a decade, Labiotech. Can they survive what are likely to be leaner times ahead?. To bolster Europe’s biotech venture capital ecosystem, investment firms and research institutions launched the European Life Sciences Coalition. Availability of treatments - Accelerating the development and delivery of groundbreaking treatments. The biotech industry in Europe is booming, with companies making groundbreaking medical advances, from oncology and gene therapy to immunology and rare diseases. As global food systems reorient for resilience and sustainability, biotechnology innovations that succeed in Europe have market potential well beyond the continent’s borders. Regarded as one of the most promising technological areas of the century, these technologies hold great potential to help the EU modernise its agriculture, forestry, energy, food and feed sectors as well as its industry. It must be bold, addressing the fundamental frameworks through which biotechnology innovation is anchored, grown and delivered in the EU from its rich heritage of research and invention. eu offers trusted insights and updates for the global life sciences community. 1 The MDR, introduced to address safety gaps under the former Medical Device Directive, has changed how medical devices are evaluated, monitored, and maintained UK remains Europe’s biggest biotech venture market Despite the overall decline in venture funding, the UK retained its position as Europe’s leading national biotech market, representing 30% of all European venture financing in 2025. s8vxls, vwukw, qnndz, xq5ax, v7olr, 19rnp, e3ao, bmpa, klmih, qpfe,